Core Insights - NeuroSense Therapeutics has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, a treatment for amyotrophic lateral sclerosis (ALS) [13][14] - The agreement includes a substantial upfront payment, funding for a Phase 3 clinical trial, milestone payments, and a tiered royalty structure reaching double-digit percentages on annual net sales [14][15] - PrimeC is a proprietary fixed-dose combination of two FDA-approved drugs, designed to target multiple ALS disease pathways, and has shown positive results in a Phase 2b clinical trial [4][7] Company Overview - NeuroSense Therapeutics is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's [9] - The company aims to address significant unmet medical needs through combined therapies targeting multiple disease pathways [9] Industry Context - ALS is an incurable neurodegenerative disease with a high annual disease burden of $1 billion in the U.S., affecting over 5,000 new patients each year [5] - The prevalence of ALS is expected to grow by 24% by 2040 in the U.S. and EU, highlighting the urgent need for effective treatments [5]
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS